William T Shearer1, Elizabeth Dunn2, Luigi D Notarangelo3, Christopher C Dvorak2, Jennifer M Puck2, Brent R Logan4, Linda M Griffith5, Donald B Kohn6, Richard J O'Reilly7, Thomas A Fleisher8, Sung-Yun Pai9, Caridad A Martinez10, Rebecca H Buckley11, Morton J Cowan2. 1. Department of Pediatrics, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, Tex. Electronic address: wtshearer@texaschildrens.org. 2. Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplant, Benioff Children's Hospital, University of California San Francisco, San Francisco, Calif. 3. Division of Biostatistics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wis. 4. Division of Immunology and the Manton Center for Orphan Disease Research, Children's Hospital Boston, and Harvard Stem Cell Institute, Harvard Medical School, Boston, Mass. 5. Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 6. Departments of Microbiology, Immunology & Molecular Genetics and Pediatrics, University of California, Los Angeles, Calif. 7. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY. 8. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md. 9. Division of Hematology and Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Mass. 10. Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital Cancer Center, Houston, Tex. 11. Department of Pediatrics and Immunology, Duke University Medical Center, Durham, NC.
Abstract
BACKGROUND: The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and related disorders varies among institutions and countries. OBJECTIVES: The Primary Immune Deficiency Treatment Consortium attempted to develop a uniform set of criteria for diagnosing SCID and related disorders and has evaluated the results as part of a retrospective study of SCID in North America. METHODS: Clinical records from 2000 through 2009 at 27 centers in North America were collected on 332 children treated with hematopoietic stem cell transplantation (HCT), enzyme replacement therapy, or gene therapy for SCID and related disorders. Eligibility for inclusion in the study and classification into disease groups were established by using set criteria and applied by an expert review group. RESULTS: Two hundred eighty-five (86%) of the patients were determined to be eligible, and 47 (14%) were not eligible. Of the 285 eligible patients, 84% were classified as having typical SCID; 13% were classified as having leaky SCID, Omenn syndrome, or reticular dysgenesis; and 3% had a history of enzyme replacement or gene therapy. Detection of a genotype predicting an SCID phenotype was accepted for eligibility. Reasons for noneligibility were failure to demonstrate either impaired lymphocyte proliferation or maternal T-cell engraftment. Overall (n = 332) rates of testing were as follows: proliferation to PHA, 77%; maternal engraftment, 35%; and genotype, 79% (mutation identified in 62%). CONCLUSION: Lack of complete laboratory evaluation of patients before HCT presents a significant barrier to definitive diagnosis of SCID and related disorders and prevented inclusion of subjects in our observational HCT study. This lesson is critical for patient care, as well as the design of future prospective treatment studies for such children because a well-defined and consistent study population is important for precision in outcomes analysis. Published by Mosby, Inc.
BACKGROUND: The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and related disorders varies among institutions and countries. OBJECTIVES: The Primary Immune Deficiency Treatment Consortium attempted to develop a uniform set of criteria for diagnosing SCID and related disorders and has evaluated the results as part of a retrospective study of SCID in North America. METHODS: Clinical records from 2000 through 2009 at 27 centers in North America were collected on 332 children treated with hematopoietic stem cell transplantation (HCT), enzyme replacement therapy, or gene therapy for SCID and related disorders. Eligibility for inclusion in the study and classification into disease groups were established by using set criteria and applied by an expert review group. RESULTS: Two hundred eighty-five (86%) of the patients were determined to be eligible, and 47 (14%) were not eligible. Of the 285 eligible patients, 84% were classified as having typical SCID; 13% were classified as having leaky SCID, Omenn syndrome, or reticular dysgenesis; and 3% had a history of enzyme replacement or gene therapy. Detection of a genotype predicting an SCID phenotype was accepted for eligibility. Reasons for noneligibility were failure to demonstrate either impaired lymphocyte proliferation or maternal T-cell engraftment. Overall (n = 332) rates of testing were as follows: proliferation to PHA, 77%; maternal engraftment, 35%; and genotype, 79% (mutation identified in 62%). CONCLUSION: Lack of complete laboratory evaluation of patients before HCT presents a significant barrier to definitive diagnosis of SCID and related disorders and prevented inclusion of subjects in our observational HCT study. This lesson is critical for patient care, as well as the design of future prospective treatment studies for such children because a well-defined and consistent study population is important for precision in outcomes analysis. Published by Mosby, Inc.
Authors: D Moshous; L Li; R Chasseval; N Philippe; N Jabado; M J Cowan; A Fischer; J P de Villartay Journal: Hum Mol Genet Date: 2000-03-01 Impact factor: 6.150
Authors: Corinne Antoine; Susanna Müller; Andrew Cant; Marina Cavazzana-Calvo; Paul Veys; Jaak Vossen; Anders Fasth; Carsten Heilmann; Nicolas Wulffraat; Reinhard Seger; Stéphane Blanche; Wilhelm Friedrich; Mario Abinun; Graham Davies; Robert Bredius; Ansgar Schulz; Paul Landais; Alain Fischer Journal: Lancet Date: 2003-02-15 Impact factor: 79.321
Authors: Marcella Sarzotti; Dhavalkumar D Patel; Xiaojing Li; Daniel A Ozaki; Shui Cao; Scott Langdon; Roberta E Parrott; Katherine Coyne; Rebecca H Buckley Journal: J Immunol Date: 2003-03-01 Impact factor: 5.422
Authors: M Noguchi; H Yi; H M Rosenblatt; A H Filipovich; S Adelstein; W S Modi; O W McBride; W J Leonard Journal: Cell Date: 1993-04-09 Impact factor: 41.582
Authors: Joseph L Roberts; Andrea Lengi; Stephanie M Brown; Min Chen; Yong-Jie Zhou; John J O'Shea; Rebecca H Buckley Journal: Blood Date: 2003-11-13 Impact factor: 22.113
Authors: Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; Sung-Yun Pai; Barbara Ballard; Sarah C Bauer; Jack J H Bleesing; Marcia Boyle; Amy Brower; Rebecca H Buckley; Mirjam van der Burg; Lauri M Burroughs; Fabio Candotti; Andrew J Cant; Talal Chatila; Charlotte Cunningham-Rundles; Mary C Dinauer; Christopher C Dvorak; Alexandra H Filipovich; Thomas A Fleisher; Hubert Bobby Gaspar; Tayfun Gungor; Elie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary Hurley; Sumathi Iyengar; Elizabeth M Kang; Brent R Logan; Janel R Long-Boyle; Harry L Malech; Sean A McGhee; Fred Modell; Vicki Modell; Hans D Ochs; Richard J O'Reilly; Robertson Parkman; David J Rawlings; John M Routes; William T Shearer; Trudy N Small; Heather Smith; Kathleen E Sullivan; Paul Szabolcs; Adrian Thrasher; Troy R Torgerson; Paul Veys; Kenneth Weinberg; Juan Carlos Zuniga-Pflucker Journal: J Allergy Clin Immunol Date: 2013-10-15 Impact factor: 10.793
Authors: C C Dvorak; K Patel; J M Puck; J Wahlstrom; M J Dorsey; R Adams; J Facchino; M J Cowan Journal: Bone Marrow Transplant Date: 2017-04-24 Impact factor: 5.483
Authors: Kerstin Felgentreff; Yu Nee Lee; Francesco Frugoni; Likun Du; Mirjam van der Burg; Silvia Giliani; Ilhan Tezcan; Ismail Reisli; Ester Mejstrikova; Jean-Pierre de Villartay; Barry P Sleckman; John Manis; Luigi D Notarangelo Journal: J Allergy Clin Immunol Date: 2015-04-25 Impact factor: 10.793
Authors: Sebastian Fuchs; Anne Rensing-Ehl; Ulrich Pannicke; Myriam R Lorenz; Paul Fisch; Yogesh Jeelall; Jan Rohr; Carsten Speckmann; Thomas Vraetz; Susan Farmand; Annette Schmitt-Graeff; Marcus Krüger; Brigitte Strahm; Philipp Henneke; Anselm Enders; Keisuke Horikawa; Christopher Goodnow; Klaus Schwarz; Stephan Ehl Journal: Blood Date: 2015-08-19 Impact factor: 22.113